WO2012034352A1 - 使人的体细胞逆向分化产生自体生殖干细胞的方法、试剂盒及其应用 - Google Patents

使人的体细胞逆向分化产生自体生殖干细胞的方法、试剂盒及其应用 Download PDF

Info

Publication number
WO2012034352A1
WO2012034352A1 PCT/CN2011/001393 CN2011001393W WO2012034352A1 WO 2012034352 A1 WO2012034352 A1 WO 2012034352A1 CN 2011001393 W CN2011001393 W CN 2011001393W WO 2012034352 A1 WO2012034352 A1 WO 2012034352A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
interleukin
cell
autologous
stem cells
Prior art date
Application number
PCT/CN2011/001393
Other languages
English (en)
French (fr)
Inventor
林雄斌
Original Assignee
Lin Xiongbin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lin Xiongbin filed Critical Lin Xiongbin
Publication of WO2012034352A1 publication Critical patent/WO2012034352A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Definitions

  • the present invention relates to the field of biomedical technology, and in particular, to a cell culture method for producing human autologous stem cells by reverse differentiation of human somatic cells and uses thereof. Background technique
  • germline stem cells in the gonads are derived from a rare number of primordial germ cells that are passed from the embryo. During embryogenesis and ovarian or testicular formation, primordial germ cells only colonize the ovaries or testes. Differentiation in the ovary or testis, development and formation of mature follicles and eggs or sperm is a process of consumption.
  • the ovarian germline stem cells the original egg cells will be depleted, and the ovary will no longer have original egg cells and follicular cells.
  • the main source of estrogen also occurs simultaneously. Depletion; ovarian atrophy becomes smaller, and the ovaries age.
  • Natural germline stem cells can not only differentiate into gametes including sperm and eggs, but also have reproductive functions, or a pluripotent stem cell capable of differentiating into various cells and tissues, and have a regenerative repair function. Moreover, reproductive stem cells also have certain The degree of proliferation and passaging ability is the only thousand cells that can replicate and transmit genetic information. Therefore, autologous germline stem cells are used in the treatment of diseases and injuries of the reproductive system, in the field of repair and treatment of male and female infertility, in the field of anti-aging health care and life extension applications, and in the field of establishing autologous reproductive stem cell banks. Important value and meaning.
  • germline stem cells There are two main methods used in the world to prepare germline stem cells.
  • One method is to form allogeneic germ cells by in vitro differentiation of natural embryonic stem cells, and is applied to the research field;
  • the second method is to prepare autologous germline stem cells from the testis or ovary, and to apply infertility treatment field, separation and culture time-consuming Difficulties, the source of germ cells is difficult, and the number of acquisitions is extremely rare.
  • Somatic cells are progeny cells that have been produced by the directional differentiation of stem cells and have specific functions.
  • the chromosomal DNA of somatic cells and the chromosomal DNA of stem cells do not differ in the number of genes and genes.
  • the main difference between somatic cells and thousand cells may be that some functional genes are Different active expression states. Differences in functional gene expression determine differences in specific functions and morphologies of cells.
  • the stem cell characteristics of stem cells determine that the gene switch is turned off, and then the stem cells differentiate to form somatic cells with a specific function; in other words, in vivo Germline stem cell determinants, such as Oct4, Nanog, C-kit, Dazl, and Mvh genes, are still present in the chromosomal DNA sequence of cells, and these genes are only in a closed or quiescent state.
  • in vivo Germline stem cell determinants such as Oct4, Nanog, C-kit, Dazl, and Mvh genes, are still present in the chromosomal DNA sequence of cells, and these genes are only in a closed or quiescent state.
  • the use of certain substances to open the germ cell characteristics of somatic DNA sequences determines the gene switches such as Oct4, Nanog, C-kit, Dazl and Mvh, and these somatic cells may re-transform to form new autologous germ cells.
  • the differentiation of human somatic cells from blood mononuclear cells and the like rapidly produces tens of millions of levels of autologous germline stem cells, providing a new unique pluripotent not only for the potential treatment of diseases and anti-aging health care.
  • Stem cells and also provide the possibility for individuals of all ages to establish autologous germ cell banks and permanently preserve autologous germ cells with unique genetic information. Summary of the invention
  • the technical problem to be solved by the present invention is to develop a new human stem cell reverse differentiation to produce autologous germ cell stem cell production regulation technology without inserting any foreign gene or DNA fragment without changing the human somatic chromosomal DNA sequence.
  • the in vitro reactivation of the germ cell characteristics in the somatic DNA sequence determines the gene switch, allowing these somatic cells to re-transform to form new germline stem cells;
  • long-term preservation of plant and protein-induced human autologous stem cells by water freezing establishes a library of individual plant and protein-induced autologous reproductive stem cells.
  • an object of the present invention to provide a method for reversely dividing human somatic cells to produce autologous germline stem cells.
  • Another object of the present invention is to provide autologous germline stem cells produced by the method and their use in the preparation of a medicament for treating various diseases.
  • Still another object of the present invention is to provide a plurality of cell culture solutions containing plant extracts and proteins used in the above method and the use of the culture solution. Further, the present invention provides a corresponding kit for preparing autologous germline stem cells.
  • the invention provides a method for producing a self-derived stem cell by reverse-differentiating human somatic cells, wherein the method comprises:
  • cell culture medium B1 which is RPMI 1640, and contains Epimedium extract 5-100 mg/ml, antler extract 5-100 mg/ml, ⁇ -27632 1-25 ⁇ , Stem cell factor 1-lOOng/mK ⁇ 3 (IL-3) 1-lOOng/mK interleukin-6 (IL-6) l-100ng/ml; then cultured for 6-9 days using cell culture medium B2, which is RPMI 1640 and contains Epimedium extract 5-100mg/mK Antler extract 5-100mg/mK Leech extract 5-100mg/ml, erythropoietin (EPO) 1-lOOng/mK Stem cell factor l-100ng/ml, alkaline Fibroblast growth factor (bFGF) 1-lOOng/mL ⁇ -27632 1-25 ⁇ , interleukin 3 l-100ng/ml, interleukin 6 l-100ng/ml, interleukin 11 (IL-1 1 )
  • the cell culture is carried out under conditions of 5% CO 2 and 37 °C.
  • the human somatic cells include, but are not limited to, human skin cells, blood nucleated cells, fat cells, cord blood cells, and placental cells.
  • a culture medium B Prior to human somatic cell to a culture medium B, first at a density of 2-5x l0 6 culturing at 5% C0 2 and 37 ° C for 24-48 hours conditions.
  • the cells are first cultured for 3 days in the cell culture solution B1, which comprises 50 mg/ml of Epimedium extract, 50 mg/ml of antler extract, ⁇ -27632 10 ⁇ , and 10 ng of stem cell factor.
  • Ml interleukin 3 lOng/mK interleukin 6 10 ng/ml of RPMI 1640; then cultured for 8 days with cell culture solution B2 containing epimedium extract 50 mg/m], antler Extract 50mg/ni], leech extract 50mg/m, erythropoietin 10 ng/mK stem cell factor 10 ng/mK basic fibroblast growth factor 10 ng/mK ⁇ -27632 10 ⁇ , interleukin 3 10ng /ml, interleukin 6 10 ng/mK interleukin 1 1 10 ng/ml of RPMI 1640, thereby obtaining plant and protein-induced autologous germline stem cells.
  • the stem cells are expanded and passaged, and the cell culture liquid B3 is RPMI 1640, and contains antler extract 5-100 mg/ml, leech extract 5-100 mg/ml, activin A 1-lOOng/mK.
  • GDNF GDNF
  • EPO erythropoietin
  • the plant and protein-inducible autologous germline stem cells are cultured to a density of 100%, they are diluted 1:3 and cultured in cell culture medium B3.
  • the amplification passage of the cells is carried out at 5% CO 2 and 37 ° C.
  • the cell culture solution B3 is used to contain antler extract 50 mg/ml, leech extract 50 mg/ml, activin A 10 ng/ml, gel shield cell-derived neurotrophic factor 10 ng/ml, red-promoting Cytopoietin 10 ng/ml, stem cell factor 10 ng/ml, basic fibroblast growth factor 10 ng/ml, interleukin 3 lOng/mK interleukin 6 10 ng/mK interleukin 11 10 ng/ml, insulin RPMI 1640 at 10 ng/ml.
  • the method of cryopreservation is: mixing the produced plant and protein-induced autologous germline stem cells with a cell density of 1 ⁇ 10 1 G /ml and a concentration of 10% dimercapto sulfoxide and 10% low molecular dextran. , cool to -80 ° C, then transfer to -186 ° C liquid nitrogen in deep cryopreservation.
  • the invention provides a plant and protein-induced autologous germline stem cell prepared by the above method.
  • the present invention also provides the use of the plant and protein-inducing autologous reproductive cells.
  • the present invention provides the autologous germline stem cells for preparing a medicament for treating male and female infertility and for treating regenerative organ regeneration.
  • a diseased drug for repair preferably, the disease is ovarian failure;
  • the present invention provides the use of the autologous germline stem cell in establishing a library of autologous germline stem cells.
  • the present invention provides a culture solution for reversely differentiating human somatic cells, wherein the culture solution is selected from the group consisting of cell culture fluids B1, B2, and B3, and the cell culture fluid B1 is RPMI 1640 and contains epimedium.
  • the cell culture solution B2 is RPMI 1640, and contains Epimedium extract 5-100 mg/ml, pilose antler extract 5-100 mg/ml, leech extract 5-100 mg/ml, erythropoietin 1-100 ng/ml.
  • the cell culture solution B3 is RPMI 1640, and contains antler extract 5-100mg/mK leech extract 5-100mg/ml, activin A l-100ng/ml, gel shield cell-derived nerve Nutritional factor l-100ng/ml, erythropoietin 1-100ng/ml, stem cell factor 1-100ng/ml, basic fibroblast growth factor 1-100ng/ml, white blood cell 3 1-lOOng / mK interleukin 6 l-100ng / ml, interleukin-11 1-lOOng / mK insulin
  • the present invention provides the use of the cell culture fluids B1 and B2 for the reverse differentiation of human somatic cells to produce autologous germ cells.
  • the present invention also provides the use of the cell culture fluid B3 in the expansion and passage of autologous germline stem cells.
  • the present invention provides a kit for preparing autologous germline stem cells, wherein The kit includes cell culture fluids B1 and B2;
  • the kit further comprises human somatic cells; the somatic cells include, but are not limited to, human skin cells, blood nucleated cells, fat cells, cord blood cells, placental cells.
  • the kit further comprises cell culture fluid B3.
  • the present invention also provides the use of the kit in the preparation of autologous germline stem cells and a medicament for treating male and female infertility and for treating a disease drug involving organ regeneration and repair; preferably, the disease is an ovary Depletion.
  • a disease drug involving organ regeneration and repair preferably, the disease is an ovary Depletion.
  • the raw material cells of the selected human body can be: A. cord blood, B. placenta, C. cell professional company commercialized non-immortalized human body cell strain, D. cell professional company commercialization provides immortalization Human various somatic cell strains, E. Blood and white blood cell suspensions preserved in conventional blood banks, F. Freshly isolated human skin cells, blood nucleated cells, fat cells, etc.; G Partial health discarded due to surgical resection Tissue organs such as brain, muscle, liver, spleen, kidney, bone, and adipose tissue.
  • the human body cells selected for use may be: human skin cells, blood nucleated cells, fat cells, cord blood, and a placenta.
  • Culturing selected cells in the starting material comprising: a density of 2-5xl0 6, with the corresponding cell culture media like DMEM cultured under 5% C0 2 at 37 ° C and the conditions for 24-48 hours.
  • the reverse differentiation of the raw material cells to produce the human autologous germ cells includes: the corresponding raw body cells are cultured in a corresponding cell culture medium such as DMEM at 5% CO 2 and 37 ° C for 24-48 hours, and then replaced with the cell culture solution Bl.
  • a corresponding cell culture medium such as DMEM at 5% CO 2 and 37 ° C for 24-48 hours
  • the resulting plant and protein-induced autologous germline stem cells can be expanded and passaged using the following procedure: Cell culture medium B3 (RPMI 1640, antler extract 50 mg/ml, mink extract 50 mg/ml, activin A 10 ng/ml, Glial cell-derived neurotrophic factor 10 ng/ml, erythropoietin 10 ng ml, stem cell factor 10 ng/ml, basic fibroblast growth factor 10 ng/mK interleukin 3 lOng/mK interleukin-6 lOng/mL interleukin 11 10 ng/ml, insulin 10 ng/ml)
  • Cell culture medium B3 RPMI 1640, antler extract 50 mg/ml, mink extract 50 mg/ml, activin A 10 ng/ml, Glial cell-derived neurotrophic factor 10 ng/ml, erythropoietin 10 ng ml, stem cell factor 10 ng/ml, basic fibroblast
  • the produced plant and protein-inducible human autologous germ cells are preserved for a long period of time by freezing: the plant and protein-induced germ-derived stem cells grown in suspension are suspended and collected in a 50 ml milliliter centrifuge tube, The centrifuge was centrifuged at 1500 rpm for 10 minutes at 4 ° C, and the supernatant was discarded.
  • the prepared plant and protein-induced germ cells were mixed with 1 ⁇ 10 1 G /ml and DMSO to 10% dimethyl sulfoxide and 10°/.
  • the low molecular weight dextrose liver concentration was mixed, cooled to -80 ° C, and then transferred to -186 ° C liquid nitrogen for cryopreservation.
  • the technical method of the invention can be applied to the treatment of male and female infertility, and is suitable for anti-aging health care of autologous stem cells, and regenerating and repairing whole body tissues by using a large number of autologous germ cells.
  • the aging and degeneration of organs, especially the failure of the ovary, can restore the young structure and physiological functions of tissues and organs, anti-aging and longevity.
  • the in vitro induced differentiation of autologous germline stem cells has a major role in the development of contraceptives, population regulation, preservation of endangered species, animal breeding and production of transgenic animals.
  • the present invention has at least the following advantages:
  • the present invention differs from the existing use of genetic recombination technology to induce somatic cell reverse differentiation to produce stem cells (iP stem cells), provides a new somatic cell reverse differentiation, produces human autologous germ cell production regulation technology, and utilizes plant extracts. And the protein formula technology induces stem cells (Plants of the pluripotent stem cells), which makes the cells close to the natural cells and has high safety.
  • the present invention employs a conventionally optimized somatic cell, a plant extract and a protein formulation which are subjected to screening optimization design without changing the somatic chromosomal DNA sequence without inserting any foreign gene or DNA fragment.
  • the cells re-differentiate to form autologous germline stem cells, which provides new ideas and ways to solve the current difficulties in the field of infertility treatment. It overcomes the difficulty in isolation and culture of autologous germ cells isolated from testis or ovary. The source of cells is difficult to obtain and the number of defects is extremely rare.
  • the method of the present invention can directly adopt the somatic cells from the patient, and the somatic cells can be reversely differentiated to produce autologous germline stem cells.
  • the use of the autologous germline stem cells avoids the immune rejection caused by the allogeneic/heterologous stem cell transplantation, and provides a clinical application.
  • Significant convenience In the two groups of transplanted mice, the rats were subcutaneously transplanted with lxlO 8 plant and protein-induced germline stem cells or lxlO 8 human natural embryonic stem cells to observe whether there was tumor formation at the inoculation site.
  • the invention is also a novel technical method for producing germline stem cells in human subjects of any age.
  • the method of the present invention can produce 200 ml of human peripheral blood in the range of tens of billions of first-generation autologous/allogeneic germ cells in 2 weeks, and the production speed is fast, the yield is huge, and the purity reaches 15-50%.
  • a large number of autologous reproductive stem cells are rapidly produced in the short term.
  • the production processes of various plant and protein-induced human autologous stem cells can be detected strictly, repeatedly, systematically by flow cytometry and immunocytochemistry techniques.
  • plant and protein-induced human autologous reproductive cells may have good potential applications in the field of industrialization of regenerative medicine, autologous tissue engineering and autologous germ cell production. It also has the possibility of large-scale industrialization and industrial production of autologous reproductive stem cells.
  • the method of the present invention is also applicable to the establishment of an autologous reproductive stem cell bank, long-term permanent preservation of autologous reproductive stem cells and unique genetic information of individuals, and is a new technical method for establishing an autologous reproductive stem cell bank in human individuals of any age.
  • 1-A is a blood mononuclear cell PBMC (peripheral blood mononuclear cells, that is, a raw material cell);
  • 1-B is a plant and protein induced genital germ cell PPiPGC (Plants and Proteins induced primordial germ cell).
  • Figure 3 shows the specific phenotypes of Nanog, oct4, Klf4 and SOX2 for plant and protein-induced reproductive stem cells using Western blot Western blotting.
  • PBMC peripheral blood mononuclear cells (original cells).
  • FIG. 4 shows the specific phenotypes of c-kit, Dazl, Mvh and Fragilis for the detection of plant and protein-induced germline stem cells using flow cytometry.
  • PPiPGC-P2 is a second generation plant and protein induced primordial germ cell (Plants and Proteins induced primordial germ cell).
  • Figure 5-A shows the third generation of plant and protein-induced germline stem cells
  • 5-B is the sixth generation of plant and protein-induced germline stem cells.
  • the culture solution used in the examples is:
  • Cell culture fluid Bl RPMI 1640, containing Epimedium extract 50mg/ml, Antler extract 50mg/mK ⁇ -27632 10 ⁇ , Stem cell factor 10 ng/ml, Interleukin 3 1 Ong/ml, Interleukin 6 1 Ong/ml;
  • Cell culture medium B2 RPMI 1640, containing Epimedium extract 50mg/ml, Antler extract 50mg/ml, Leech extract 50mg/ml, Erythropoietin 10 ng/ml, Stem cell factor 10 ng/ml, Alkaline Fibroblast growth factor 10 ng/ml, ⁇ -27632 10 ⁇ , interleukin 3 1 Ong/ml, interleukin 6 1 Ong/ml, interleukin 11 1 Ong/ml;
  • Cell culture medium B3 RPMI 1640, containing antler extract 50mg/ml, leech extract 50mg/ml activin A 10 ng/ml, glial cell-derived neurotrophic factor 10 ng/ml, erythropoietin 10 ng/ Ml, stem cell factor 10 ng/ml, basic fibroblast growth factor 10 ng mK interleukin 3 10 ng mK interleukin 6 10 ng/mK interle
  • Epimedium extract, deer extract and leech extract were purchased from Henan Natural Plant Material Factory and Zhengzhou Yinuo Biotechnology Co., Ltd.; Y-27632 was purchased from Sigma; Stem Cell Factor, Interleukin 3, Interleukin-6 , interleukin 11, erythropoietin, basic fibroblast growth factor, activin A, cell-derived trophic factor, insulin were purchased from R&D.
  • Peripheral venous blood/umbilical cord blood was routinely anticoagulated and stored at 4 °C. Send to the stem cell production and production center within 24 hours. After the center needs to do the corresponding virus detection, enter the central computer registration process. After recording the corresponding barcode number, the blood sample enters the sterile stem cell production workshop.
  • the human autologous germ cells were tested: the specific cell phenotypes of reproductive stem cells, Nanog, Oct4, Klf4, SOX2, c-kit, Dazl, Mvh and Fragilis, were used as detection indicators, and the cell culture medium B2 was used for further culture. On the 6th, 9th and 12th day, respectively, using flow cytometry, cellular immunofluorescence technique and Western blot Western blotting technique ("Modern Immunology Experimental Techniques" Chapter 6, Chapter 7, Chapter 18 ) Detection of the rate of generation, production, production and purity of germline stem cells.
  • Plant and protein-induced autologous stem cells were cultured in cell culture medium B3 (Medium) at 5% CO 2 and 37 ° C to 100% density, diluted 1:3, and cultured in cell culture medium B3.
  • cell culture medium B3 Medium
  • Figure 5-A is the third generation of plant and protein-induced germline stem cells
  • Figure 5-B is the sixth generation of plant and protein-induced germline stem cells. Suspended adherent plants and protein-induced germ cells were collected and pooled in a 50 ml ml centrifuge tube, centrifuged at 1500 rpm for 10 minutes at 4 ° C in a centrifuge, and the supernatant was discarded.
  • the prepared plant and protein-induced germ cells were mixed with lxl0 1Q /ml and DMSO, mixed with 10% dimercaptosulfoxide and 10% low molecular weight dextrose liver, cooled to -80 ° C, and then transferred to -186 °C liquid nitrogen is stored in deep cryopreservation, and a plant and protein-induced autologous reproductive stem cell bank is established.
  • Example 2
  • mice were subcutaneously transplanted with lx lO 8 plant and protein-induced reproductive stem cells or 8 natural reproductive stem cells (granted from the reproductive center of Hainan Medical College) to observe whether there was tumor formation at the inoculation site. Continuous observation for 90 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

使人的体细胞逆向分化产生自体生殖干细胞的
方法、 试剂盒及其应用 技术领域
本发明涉及领域属于生物医学技术领域, 具体而言, 本发明涉及一种使 人的体细胞逆向分化产生自体生殖干细胞的细胞培养方法及其应用。 背景技术
在哺乳动物中, 生殖腺里的生殖干细胞来源于一种从胚胎传留下来的数 量稀少的原始生殖干细胞。 胚胎形成及卵巢或睾丸形成的过程中, 原始生殖 干细胞就只定居卵巢或睾丸。 在卵巢或睾丸分化、 发育和形成成熟的卵泡及 卵子或精子是一个消耗过程。女性一生中,经过 400至 500次卵泡发育成熟、 排卵和月经形成后, 卵巢的生殖干细胞: 原卵细胞就会枯竭, 卵巢中就不再 有原卵细胞和卵泡细胞,雌激素的主要来源也同时发生枯竭;卵巢萎缩变小, 卵巢就衰老了。 多数情况下, 男性 65岁开始睾丸的原始生殖干细胞也会逐 渐枯竭。衰老枯竭的卵巢或睾丸使男女性不可避免地走向机体整体衰老的阶 段, 并且, 影响男女性的寿命。
自然的生殖干细胞不仅能分化形成包括精子和卵子在内的配子, 具有生 殖功能, 还是一种能够分化形成多种细胞和组织的多能干细胞, 具有再生性 修复功能; 而且, 生殖干细胞还具有一定程度的增殖和传代能力, 是唯一的 能够复制和传递遗传信息的千细胞。 所以, 自体生殖干细胞在生殖系统的疾 病和损伤的治疗领域, 在男女性不孕不育的修复治疗应用领域, 在抗衰老保 健和延长寿命的应用领域以及建立自体生殖干细胞库的领域都有着十分重 要的价值和意义。
现在国际上主要采用两种方法制备生殖干细胞。一种方法是通过自然的 胚胎干细胞体外分化形成异体生殖细胞, 应用于研究领域; 第二种方法是从 睾丸或卵巢分离培养制备自体生殖干细胞, 应用不孕不育的治疗领域, 分离 培养耗时困难, 生殖细胞来源困难, 获取数量极其稀少。
体细胞是干细胞顺向分化产生的, 具有某些具体功能的子代细胞。 体细 胞的染色体 DNA和干细胞的染色体 DNA在基因结构和基因的数量上并不 存在差异。体细胞和千细胞之间的最主要的差别可能只是某些功能基因处于 不同的活性表达状态。功能基因表达的差异决定了细胞的具体功能和形态的 差异。 我们推测, 干细胞向体细胞顺向分化的程序启动后, 干细胞本身的干 细胞特性决定基因的开关就被关闭, 随后, 干细胞就分化形成了具有某种特 定功能的体细胞;换句话说, 在体细胞染色体 DNA序列中仍然存在生殖干 细胞特性决定基因, 例如 Oct4、 Nanog、 C-kit、 Dazl和 Mvh基因等, 这些 基因只是处于关闭或静止状态。 利用某些物质打开体细胞 DNA序列中的生 殖干细胞特性决定基因 Oct4、 Nanog、 C-kit、 Dazl和 Mvh等基因开关, 这 些体细胞就可能重新逆向分化而形成新的自体生殖干细胞。
在本项发明中, 从血液单个核细胞等人的体细胞逆向分化, 迅速产生百 亿数量级别的自体生殖干细胞, 不仅为疾病的潜在治疗和抗衰老保健提供了 一种新的独特的多能干细胞, 而且也为每一个不同年龄的人提供了建立自体 生殖干细胞库, 永久保存具有独特遗传信息的自体生殖细胞的潜在可能性。 发明内容
本发明所要解的技术问题是:研发一种新的人的体细胞逆向分化产生自 体生殖干细胞的干细胞生产调控技术, 在不改变人的体细胞染色体 DNA序 列, 不插入任何外来基因或 DNA片段的情况下, 应用含有某些植物提取物 和蛋白的一系列配方, 在体外重新激活体细胞 DNA序列中的生殖千细胞特 性决定基因开关,使这些体细胞重新逆向分化而形成新的生殖干细胞; 另夕卜, 经水冻长期保存植物和蛋白诱导性人自体生殖干细胞,建立个人的植物和蛋 白诱导性自体生殖干细胞库。
为了解决上述技术问题,本发明的一个目的是提供使人的体细胞逆向分 化产生自体生殖干细胞的方法。本发明的另一个目的是提供采用该方法产生 的自体生殖干细胞以及其在制备治疗多种疾病的药物中的应用。本发明的再 一个目的是提供在上述方法中所采用的含有植物提取物和蛋白的多种细胞 培养液以及该培养液的应用。 此外, 本发明还提供相应的用于制备自体生殖 干细胞的试剂盒。
本发明的目的是通过以下技术方案来实现的:
一方面, 本发明提供一种使人的体细胞逆向分化产生自体生殖干细胞的 方法, 其中, 所述方法包括:
将人的体细胞在细胞培养液 B1 中培养 2-3天, 所述细胞培养液 B1为 RPMI 1640, 并含有淫羊藿提取物 5-100mg/ml、 鹿茸提取物 5-100mg/ml、 Υ-27632 1-25μΜ、 干细月包因子( Stem cell factor ) 1-lOOng/mK 白细月包介素 3 ( IL-3 ) 1-lOOng/mK 白细胞介素 6 ( IL-6 ) l-100ng/ml; 然后换用细胞培养 液 B2培养 6-9天, 所述细胞培养液 B2为 RPMI 1640, 并含有淫羊藿提取物 5-100mg/mK 鹿茸提取物 5-100mg/mK 水蛭提取物 5-100mg/ml、 促红细胞 生成素(EPO ) 1-lOOng/mK 干细胞因子 l-100ng/ml、 碱性成纤维细胞生长 因子(bFGF ) 1-lOOng/mL Υ-27632 1-25μΜ、 白细胞介素 3 l-100ng/ml、 白 细胞介素 6 l-100ng/ml、 白细胞介素 11 ( IL-1 1 ) l-100ng/ml, 从而获得植物 和蛋白诱导性自体生殖干细胞。
优选地, 在 5%C02和 37°C条件下进行细胞培养。
在上述方法中, 所述人的体细胞包括但不限于人的皮肤细胞、 血液有核 细胞、 脂肪细胞、 脐带血细胞、 胎盘细胞。
优选地,在将人的体细胞以细胞培养液 B 1培养之前,先以 2-5x l06的密 度, 在 5%C02和 37°C条件下培养 24-48小时。
优选地, 先将细胞在细胞培养液 B1 中培养 3天, 所述细胞培养液 B1 为含有淫羊藿提取物 50mg/ml、 鹿茸提取物 50mg/ml、 Υ-27632 10μΜ、 干细 胞因子 10 ng/ml、 白细胞介素 3 lOng/mK 白细胞介素 6 10ng/ml的 RPMI 1640; 然后换用细胞培养液 B2培养 8天, 所述细胞培养液 B2为含有淫羊 藿提取物 50mg/m】、 鹿茸提取物 50mg/ni】、 水蛭提取物 50mg/m〗、 促红细 胞生成素 10 ng/mK 干细胞因子 10 ng/mK 碱性成纤维细胞生长因子 10 ng/mK Υ-27632 10μΜ、 白细胞介素 3 10ng/ml、 白细胞介素 6 10ng/mK 白细 胞介素 1 1 10ng/ml的 RPMI 1640,从而获得植物和蛋白诱导性自体生殖干细 胞。 殖干细胞进行扩增和传代, 所述细胞培养液 B3为 RPMI 1640, 并含有鹿茸 提取物 5-100mg/ml、 水蛭提取物 5-100mg/ml、 激活素 A ( Activin A ) 1-lOOng/mK 胶盾细胞源性神经营养因子( GDNF ) Ι-lOOng/mK 促红细胞生 成素 (EPO ) l-100ng/ml, 干细胞因子 l-100ng/ml、 碱性成纤维细胞生长因 子 l-100ng/ml、 白细胞介素 3 Ι-lOOng/mK 白细胞介素 6 Ι-lOOng/mK 白细胞 介素 1 1 l-100ng/ml、 胰岛素 l-100ng/ml;
优选地, 当培养植物和蛋白诱导性自体生殖干细胞至 100%密度后, 1 :3 稀释传代, 继续用细胞培养液 B3培养。
优选地, 所述细胞的扩增传代在 5%C02和 37°C条件下进行。
优选地, 采用细胞培养液 B3为含有鹿茸提取物 50mg/ml、 水蛭提取物 50mg/ml、 激活素 A 10 ng/ml、 胶盾细胞源性神经营养因子 10 ng/ml、 促红 细胞生成素 10 ng/ml、 干细胞因子 10 ng/ml、 碱性成纤维细胞生长因子 10 ng/ml、白细胞介素 3 lOng/mK白细胞介素 6 10ng/mK白细胞介素 11 10ng/ml、 胰岛素 10 ng/ml的 RPMI 1640。 的步骤;' 优选地, 所 冷冻保存方法为: 将产生的植物和蛋白诱导性自体 生殖干细胞以 1 X 101G/ml的细胞密度与 10%二曱基亚砜和 10%低分子右旋 糖酐浓度混合, 降温至 -80°C, 然后转移到 -186°C液氮中深低温保存。
另一方面,本发明提供由上述方法制备的植物和蛋白诱导性自体生殖干 细胞。
本发明还提供所述的植物和蛋白诱导性自体生殖千细胞的应用, 优选 地 ,本发明提供该自体生殖干细胞在制备用于治疗男女性不孕不育的药物和 用于治疗涉及器官再生再造和修复的疾病药物中的应用; 优选地, 所述疾病 为卵巢衰竭;优选地, 本发明提供该自体生殖干细胞在建立自体生殖干细胞 库中的应用。
又一方面, 本发明提供用于使人的体细胞逆向分化的培养液, 所述培养 液选自细胞培养液 Bl、 B2和 B3, 所述细胞培养液 B1为 RPMI 1640, 并含 有淫羊藿提取物 5-100mg/ml、 鹿茸提取物 5-100mg/mK Υ-27632 1-25μΜ、 干细胞因子 l-100ng/ml、白细胞介素 3 1-lOOng/mK白细胞介素 6 l-100ng/ml; 所述细胞培养液 B2为 RPMI 1640, 并含有淫羊藿提取物 5-100mg/ml、 鹿茸 提取物 5-100mg/ml、水蛭提取物 5-100mg/ml、促红细胞生成素 l-100ng/ml、 干细胞因子 l-100ng/ml、 碱性成纤维细胞生长因子 l-100ng/ml、 Y-27632 1-25μΜ、 白细胞介素 3 1-lOOng/mK 白细胞介素 6 vng/ml、 白细胞介素 11 l-100ng/ml ; 所述细胞培养液 B3 为 RPMI 1640 , 并含有鹿茸提取物 5-100mg/mK 水蛭提取物 5-100mg/ml、激活素 A l-100ng/ml、胶盾细胞源性 神经营养因子 l-100ng/ml、 促红细胞生成素 l-100ng/ml、 干细胞因子 l-100ng/ml、 碱性成纤维细胞生长因子 l-100ng/ml、 白细胞介素 3 1-lOOng/mK 白细胞介素 6 l-100ng/ml、 白细胞介素 11 1-lOOng/mK 胰岛素
Figure imgf000006_0001
此外, 本发明提供所述细胞培养液 B1和 B2在培养人的体细胞使之逆 向分化产生自体生殖干细胞中的应用。
本发明还提供所述细胞培养液 B3在自体生殖干细胞扩增和传代中的应 用。
再一方面, 本发明提供一种用于制备自体生殖干细胞的试剂盒, 其中所 述试剂盒包括细胞培养液 B1和 B2;
优选地, 所述试剂盒进一步包括人的体细胞; 所述体细胞包括但不限于 人的皮肤细胞、 血液有核细胞、 脂肪细胞、 脐带血细胞、 胎盘细胞。
优选地, 所述试剂盒进一步包括细胞培养液 B3。
本发明还提供所述试剂盒在制备自体生殖干细胞和用于治疗男女性不 孕不育的药物和用于治疗涉及器官再生再造和修复的疾病药物中的应用;优 选地, 所述疾病为卵巢衰竭。 以下是本发明的详细描述:
为完成本发明涉及到以下技术问题:
( 1 )选用什么样的人的体细胞作为逆向分化生产植物和蛋白诱导性自 体生殖干细胞的原料细胞;
( 2 )怎样处理和培养各种原料细胞;
( 3 )怎样使原料细胞逆向分化生产植物和蛋白诱导性自体生殖干细胞; ( 4 )怎样扩增传代植物和蛋白诱导性自体生殖干细胞;
( 5 )怎样检测生产的人自体生殖干细胞;
( 6 )怎样冰冻长期保存植物和蛋白诱导性人自体生殖干细胞;
( 7 )怎样建立植物和蛋白诱导性人自体生殖干细胞库的系统过程以及 方法。
因此, 本发明的发明目的可以通过下述方法得以实现:
选用的人的原料体细胞可以是: A.脐带血, B.胎盘, C.细胞专业公司商 品化提供的非永生化人的各种体细胞株, D.细胞专业公司商品化提供的永生 化人的各种体细胞株, E.常规血库保存的血液和白细胞悬液, F.新鲜分离制 备的人的皮肤细胞、 血液有核细胞、 脂肪细胞等等; G因手术切除而废弃的 部分健康組织器官, 如脑、 肌肉、 肝、 脾、 腎、 骨、 和脂肪组织等。 选用的 人的原料体细胞可以是: 人的皮肤细胞、 血液有核细胞、 脂肪细胞、 脐带血 细月包、 胎盘细月包。
选用的原料体细胞的培养包括: 以 2-5xl06的密度,用 DMEM等相应的 细胞培养液在 5%C02和 37°C条件下培养 24-48小时。
使原料细胞逆向分化生产人自体生殖干细胞包括: 将相应的原料体细胞 用 DMEM等相应的细胞培养液在 5%C02和 37°C条件下培养 24-48小时后, 换用细胞培养液 Bl ( RPM 1640、 淫羊藿提取物 50mg/ml、 鹿茸提取物 50mg/ml、 Υ-27632 10μΜ、 干细胞因子 10 ng/ml、 白细胞介素 3 10ng/ml、 白 细胞介素 6 lOng/ml )继续在 5%(:02和 37°C条件下培养 2-3天, 然后换用细 胞培养液 B2 ( RPMI 1640 淫羊藿提取物 50mg/ml、鹿茸提取物 50mg/ml、 水蛭提取物 50mg/ml、促红细胞生成素 10 ng/ml、干细胞因子 10 ng/ml、碱 性成纤维细胞生长因子 10 ng/ml、 Υ-27632 ΙΟμΜ, 白细胞介素 3 10ng/ml、 白细胞介素 6 10ng/ml、 白细胞介素 11 10ng/ml )继续在 5%C02和 37°C条件 下培养 6-9天。
产生的植物和蛋白诱导性自体生殖干细胞可以采用以下步驟扩增和传 代: 用细胞培养液 B3 ( RPMI 1640、 鹿茸提取物 50mg/ml、 水蛭提取物 50mg/ml、 激活素 A 10 ng/ml、 胶质细胞源性神经营养因子 10 ng/ml、 促红 细胞生成素 10 ng ml、 干细胞因子 10 ng/ml、 碱性成纤维细胞生长因子 10 ng/mK白细胞介素 3 lOng/mK白细胞介素 6 lOng/mL白细胞介素 11 10ng/ml、 胰岛素 10 ng/ml )继续在 5%C02和 37°C条件下培养植物和蛋白诱导性自体 生殖干细胞至 100%密度后, 1:3稀释传代, 继续用细胞培养液 B3培养; 根据本发明的一个实施方案, 所获得的人自体生殖干细胞可以通过以下 方法进行检测: 利用生殖干细胞的特异细胞表型 Oct4、 Nanog、 C-kit、 Dazl 和 Mvh等作为检测指标,分别采用流式细胞仪、细胞免疫荧光技术和 Western blot蛋白印迹技术检测生殖干细胞的生成速度、 生成率、 生成数量和纯度 ( Oct4、 Nanog、 C-kit、 Dazl和 Mvh等作为检测指标及检测方法参考: 王毓 斌、 陈斌, 胚胎干细胞体外分化为生殖细胞的研究进展, 生殖与避孕, 第 28 卷第 9 期; Lacham-Kaplan O, Chy H, Trounson A (2006) Testicular cell conditioned medium supports differentiation of embryonic stem cells into ovarian structures containing oocytes. Stem Cells 24: 266-273; Jinlian Hua, Kuldip Sidhu(2008).Recent Advances in the Derivation of Germ Cells from the Embryonic Stem Cells. Stem cells and development 17:399-411 )„
根据本发明的另一个实施方案, 所产生的植物和蛋白诱导性人自体生殖 千细胞经冰冻长期保存: 吹打悬浮贴壁生长的植物和蛋白诱导性生殖干细胞 并收集到 50ml毫升的离心管内, 在离心机内以 1500rpm,4°C离心 10分钟, 弃上清。 制备的植物和蛋白诱导性生殖干细胞以 lxl01G/ml和 DMSO混合, 以 10%二甲基亚砜和 10°/。低分子右旋糖肝浓度混合, 降温至 -80°C , 然后 转移到 -186°C液氮中深低温保存。 本发明的技术方法可应用于男女性不孕不育症的治疗 , 并适用于自体干 细胞的抗衰老保健, 利用巨额数量的自体生殖干细胞再生性修复全身各组织 器官的衰老变性, 尤其是衰竭卵巢的再造, 可以恢复组织器官的年青结构及 生理功能, 抗衰老及延年益寿。 所产生的自体生殖干细胞的体外诱导分化在 避孕药开发、 人口调控、 瀕危物种的保存、 动物育种和转基因动物生产方面 都有重大作用。
与现有技术相比, 本发明至少具有以下几个优点:
一、本发明不同于已有的利用基因重组技术诱导体细胞逆向分化产生干 细胞(iP干细胞), 提供了一种新的体细胞逆向分化, 产生人自体生殖干细 胞的生产调控技术, 利用植物提取物和蛋白配方技术诱导体细胞逆向分化产 生的干细胞 ( Plants and Proteins induced pluripotent stem cell, PPiPS干细月包), 使得细胞结果接近于自然千细胞, 安全性高。 具体而言, 本发明通过采用人 的常规的体细胞, 在不改变体细胞染色体 DNA序列, 不插入任何外来基因 或 DNA片段的情况下, 应用经过筛选优化设计的植物提取物和蛋白配方使 体细胞重新逆向分化而形成自体生殖干细胞, 为解决不孕不育治疗领域目前 所存在的困难提供了新的思路和途径,克服了从睾丸或卵巢分离制备自体生 殖干细胞中分离培养耗时困难、 生殖细胞来源困难、 获取数量极其稀少的缺 陷。
二、 本发明的方法可以直接采用来自患者的体细胞, 使该体细胞逆向分 化产生自体生殖干细胞,应用此自体生殖干细胞避免了采用异体 /异种干细胞 移植带来的免疫排斥, 为临床应用提供了显著的便利条件。 在两组棵鼠移植试脸中, 棵鼠皮下移植注射 lxlO8 个植物和蛋白诱导性生 殖干细胞或 lxlO8个人自然胚胎干细胞,观察接种部位有否肿瘤形成, 连续 观察 90天后,发现采用植物和蛋白诱导性生殖干细胞的试验组 10只棵鼠无 一例产生肿瘤, 人胚胎干细胞试验组 10只棵鼠全部产生肿瘤, 因此本发明 的植物和蛋白诱导性生殖干细胞具有较高的安全性。本发明还是一种可以在 任何年龄的人个体中生产生殖干细胞的新技术方法。
四、 已证明采用本发明的方法可以使 200ml人周围血液在 2周内产生几 百亿数量级别的第 1代自体 /异体生殖干细胞, 生产速度快, 产量巨大, 纯度 达到 15-50%, 可以在任何年龄阶段的人个体中, 短期内迅速生产巨额数量 的自体生殖干细胞。 利用生殖干细胞的特异表型作为检测指标, 各种植物和 蛋白诱导性人自体干细胞的生产工艺流程可以被严格地、 多次地、 系统地进 行流式细胞技术和免疫细胞化学技术检测, 因此, 作为自体种子细胞和再生 修复细胞, 在再生医学、 自体组织器官工程和自体生殖干细胞生产的产业化 领域, 植物和蛋白诱导性人自体生殖千细胞可能具有良好的潜在应用前景, 还具有大规模工业化和产业化生产自体生殖干细胞的可能性。
五、 本发明的方法还适用于建立自体生殖干细胞库, 长期永久保存自体 生殖干细胞及个人独特的遗传信息,是一种可以在任何年龄的人个体中建立 自体生殖干细胞库的新技术方法。 附图说明
以下, 结合附图来详细说明本发明的实施例, 其中:
图 1中, 1-A为血液单个核细胞 PBMC (周围血单个核细胞, 即原料细 胞); 1-B 为植物和蛋白诱导性生殖干细胞 PPiPGC (Plants and Proteins induced primordial germ cell)。
Nanog、 oct4、 Klf4和 SOX2特异表型。
图 3为应用 Western blot蛋白印迹技术检测植物和蛋白诱导性生殖干细 胞的 Nanog、 oct4、 Klf4和 SOX2特异表型, PBMC为周围血单个核细胞(原 料细胞)。
图 4为应用流式细胞仪技术检测植物和蛋白诱导性生殖干细胞的 c-kit、 Dazl、 Mvh和 Fragilis特异表型。 PPiPGC-P2为第 2代植物和蛋白诱导性生 殖干细胞 PPiPGC (Plants and Proteins induced primordial germ cell)。
图 5中, 图 5-A为第 3代植物和蛋白诱导性生殖干细胞; 5-B为第 6代 植物和蛋白诱导性生殖干细胞。 具体实施方式
通过下面的详述, 将对本发明的操作方法及特点和优点作进一步说明, 当然, 应该指出的是尽管本文描述的以下几种实施例, 人们也可以根据本发 明的基础, 提出各种变化和个性的形式也是可能的。
实施例中采用的培养液为:
细胞培养液 Bl: RPMI 1640, 含淫羊藿提取物 50mg/ml、 鹿茸提取物 50mg/mK Υ-27632 10μΜ、 干细胞因子 10 ng/ml、 白细胞介素 3 1 Ong/ml、 白 细胞介素 6 1 Ong/ml;
细胞培养液 B2: RPMI 1640, 含淫羊藿提取物 50mg/ml、 鹿茸提取物 50mg/ml、水蛭提取物 50mg/ml、促红细胞生成素 10 ng/ml、 干细胞因子 10 ng/ml、 碱性成纤维细胞生长因子 10 ng/ml、 Υ-27632 10μΜ、 白细胞介素 3 1 Ong/ml、 白细胞介素 6 1 Ong/ml、 白细胞介素 11 1 Ong/ml; 细胞培养液 B3: RPMI 1640, 含鹿茸提取物 50mg/ml、 水蛭提取物 50mg/ml 激活素 A 10 ng/ml、 胶质细胞源性神经营养因子 10 ng/ml、 促红 细胞生成素 10 ng/ml、 干细胞因子 10 ng/ml、 碱性成纤维细胞生长因子 10 ng mK白细胞介素 3 10ng mK白细胞介素 6 10ng/mK白细胞介素 11 10ng/ml、 胰岛素 10 ng/ml。
实施例中采用的试剂及其来源:
淫羊藿提取物、鹿萆提取物和水蛭提取物购自河南天然植物原料厂和郑 州荔诺生物科技有限公司; Y-27632购自 Sigma公司; 干细胞因子、 白细胞 介素 3、 白细胞介素 6、 白细胞介素 11、 促红细胞生成素、 碱性成纤维细胞 生长因子、 激活素 A、 细胞源性营养因子、 胰岛素购自 R&D公司。 实施例: 采用周围静脉血、脐带血作为原料细胞, 生产和长期保存植物 和蛋白诱导性生殖千细胞
周围静脉血和脐带血(北京五洲女子医院、 北京安定门医院、 科研人员 捐献等) 的无菌采集。 采集周围静脉血 /脐带血前应征得供血本人或直系亲 属的同意, 并记录供血本人及家庭的遗传和传染病史以及医院所有相关的病 毒检查结果。
周围静脉血 /脐带血常规抗凝, 4°C保存。在 24小时之内送至干细胞制作 生产中心。 在中心需要再做相应的病毒检测后, 进入中心电脑登记程序, 在 记录相应的条形码编号后, 血液标本进入无菌干细胞生产车间。
在干细胞生产车间, 血液标示应用 Ficoll标准分离技术(《现代免疫学 实验技术》第十二章第 288页)分离单个核细胞后, 进行单个核细胞计数。 应用 DMEM培养液以 2-5xl06的密度, 在 5°/。C02和 37。C条件下培养 24-48 小时;换用细胞培养液 B1继续在 5%C02和 37°C条件下培养 72小时, 然后 换用细胞培养液 B2继续在 5%C02和 37°C条件下培养 9-15天。
对生产的人自体生殖干细胞进行了检测: 利用生殖干细胞的特异细胞表 型 Nanog、 Oct4、 Klf4、 SOX2、 c-kit. Dazl、 Mvh和 Fragilis等作为检测指 标, 在换用细胞培养液 B2继续培养后的第 6、 第 9和第 12天, 分别釆用流 式细胞仪、细胞免疫荧光技术和 Western blot蛋白印迹技术(《现代免疫学实 验技术》第六章、 第七章、 第十八章)检测生殖干细胞的生成速度、 生成 率、 生成数量和纯度。 结果发现, 200ml周围静脉血 /80ml脐带血的单个核 细胞在细胞培养液 B2培养后的第 6-9天, 植物和蛋白诱导性生殖干细胞的 产量可达 1-2.5x10" (其它实验结果请见附图 1-4 )。 形态, 分别如图 1A和 IB所示。 图 2中示出了应用细胞免疫荧光化学技术 检测生产的诱导性生殖干细胞的 Oct4和 Nanog特异表型。应用 Western blot 蛋白印迹技术检测植物和蛋白诱导性生殖干细胞 (PPiPGC)的 Oct4、Nanog、 Klf4和 SOX2特异表型, 并且以原料细胞 (周围血单个核细胞, PBMC)作 为对照。 由电泳结果可见, PPiPGC干细胞 Oct4、 Nanog. Klf4和 SOX2 特异表型阳性, 而 PBMC原料细胞 Oct4、 Nanog. Klf4和 SOX2特异表型 阴性。 图 4为应用流式细胞仪技术检测生产的诱导性生殖干细胞的 c-kit、 Dazl、 Mvh和 Fragilis特异表型的结果。 如图所示, 用 B2培养液培养第 6 天, c-kit、 Dazl、 Mvh和 Fragilis特异表型的生成速度分别为 6.87°/。、 28.14%、 37.13%和 16.75%。
对产生的植物和蛋白诱导性人自体生殖干细胞进行扩增传代。用细胞培 养液 B3 (Medium) 继续在 5%C02和 37°C条件下培养植物和蛋白诱导性自体 生殖干细胞至 100%密度后, 1:3稀释传代, 继续用细胞培养液 B3培养。 培 养结果请参考图 5, 其中图 5-A为第 3代植物和蛋白诱导性生殖干细胞, 图 5- B为第 6代植物和蛋白诱导性生殖干细胞。 打悬浮贴壁生长的植物和蛋白诱导性生殖干细胞并 集到 50ml毫升的离心 管内, 在离心机内以 1500rpm,4°C离心 10分钟, 弃上清。 制备的植物和蛋白 诱导性生殖干细胞以 lxl01Q/ml和 DMSO混合, 以 10%二曱基亚砜和 10% 低分子右旋糖肝浓度混合, 降温至 -80°C , 然后转移到 -186°C液氮中深低温 保存, 建立植物和蛋白诱导性自体生殖干细胞库。 实施例 2
本实施例对实施例 1 中制备的植物和蛋白诱导性自体生殖干细胞进行 棵鼠移植的安全性研究, 具体如下。
在两组棵鼠移植试验中, 棵鼠皮下移植注射 lx lO8 个植物和蛋白诱导 性的生殖干细胞或 ΙχΙΟ8个人自然生殖干细胞(海南医学院生殖中心赠送), 观察接种部位有否肿瘤形成。 连续观察 90天。
结果显示, 植物和蛋白诱导性生殖干细胞试验组 10只棵鼠无一例产生 肿瘤, 具有较高的安全性; 而人自然生殖干细胞试验组 10只棵鼠全部产生 肿瘤。

Claims

权 利 要 求 书
1、 一种使人的体细胞逆向分化产生自体生殖干细胞的方法, 其中, 所 述方法包括:
将人的体细胞在细胞培养液 B 1 中培养 2-3天, 所述细胞培养液 B 1为 RPMI 1640,并含有淫羊藿提取物 5-100mg/ml、鹿茸提取物 5-100mg mg/ml、 Υ-27632 1-25μΜ> 干细胞因子 l-100ng/ml、 白细胞介素 3 l-100ng/ml、 白细 胞介素 6 l-100ng/ml; 然后换用细胞培养液 B2培养 6-9天, 所述细胞培养液 B2 为 RPMI 1640 , 并含有淫羊藿提取物 5-100mg mg/mK 鹿茸提取物 5-100mg mg/ml 水蛭提取物 5-100mg mg/ml、促红细胞生成素 l-100ng/ml、 干细胞因子 l-100ng/ml、 碱性成纤维细胞生长因子 l-100ng/ml、 Y-27632 1-25μΜ、 白细胞介素 3 l-100ng/ml、 白细胞介素 6 l-100ng/ml、 白细胞介素 1 1 l-100ng/ml, 从而获得植物和蛋白诱导性自体生殖干细胞;
优选地, 在 5%C02和 37°C条件下进行细胞培养。
2、 如权利要求 1 所述的方法, 其中, 所述人的体细胞包括但不限于人 的脐带血细胞、 胎盘细胞、 皮肤细胞、 血液有核细胞、 脂肪细胞等;
优选地,在人的体细胞以细胞培养液 B1培养之前,先以 2-5X 106的密度 在 5%C02和 37°C奈件下培养 24-48小时;
优选地, 先将细胞在细胞培养液 B1 中培养 3天, 所述细胞培养液 B1 为含有淫羊藿提取物 50mg/ml、 鹿茸提取物 50mg/ml、 Υ-27632 ΙΟμΜ, 干细 胞因子 10 ng/ml、 白细胞介素 3 lOng/mK 白细胞介素 6 10ng/ml的 RPMI 1640; 然后换用细胞培养液 B2培养 6-8天, 所述细胞培养液 B2为含有淫早 藿提取物 50mg/ml、 鹿茸提取物 50mg/ml、 水蛭提取物 50mg/ml、 促红细 胞生成素 10 ng/mK 干细胞因子 10 ng/mU 碱性成纤维细胞生长因子 10 ng/mK Υ-27632 10μΜ、 白细胞介素 3 10ng/mK 白细胞介素 6 10ng/mK 白细 胞介素 1 1 10ng/ml的 RPMI 1640,从而获得植物和蛋白诱导性自体生殖干细 胞。
3、 如权利要求 1或 2所述的方法, 其中所述方法还包括采用细胞培养 液 B3对获得的植物和蛋白诱导性自体生殖干细胞进行扩增和传代, 所述细 胞培养液 B3 为 RPMI 1640, 并含有鹿茸提取物 5-100mg/ml、 水蛭提取物 5-100mg/m 激活素 A (激活素 A ) 1-l OOng/mK 胶质细胞源性神经营养因 子(胶质细胞源性神经营养因子) l-100ng/ml、 促红细胞生成素 (促红细胞 生成素) l-100ng/ml、 干细胞因子 l-100ng/ml、 碱性成纤维细胞生长因子 1-lOOng/mK 白细胞介素 3 l-100ng/ml、 白细胞介素 6 l-100ng/ml、 白细胞介 素 11 l-100ng/ml、 胰岛素 l-100ng/ml;
优选地, 当培养植物和蛋白诱导性自体生殖干细胞至 100%密度后, 1:3 稀释传代, 继续用细胞培养液 B3培养;
优选地, 所述细胞的扩增传代在 5%C02和 37°C奈件下进行;
优选地, 所述细胞培养液 B3为含有鹿萆提取物 50mg/ml、 水蛭提取物 50mg/ml、 激活素 A 10 ng/ml、 胶盾细胞源性神经营养因子 10 ng/ml、 促红 细胞生成素 10 ng/ml、 干细胞因子 10 ng/ml、 碱性成纤维细胞生长因子 10 ng/ml、白细胞介素 3 lOng/ml,白细胞介素 6 10ng/ml 白细胞介素 11 10ng/ml、 胰岛素 10 ng/ml的 RPMI 1640。
4、 如权利要求 1-3中任一项所述的方法, 其中, 所述方法还包括冷冻 保存使体细胞逆向分化产生的自体生殖干细胞的步骤;
优选地, 所述冷冻保存步骤包括: 将产生的植物和蛋白诱导性自体生 殖干细胞以 1 X 101()/ml的细胞密度与二曱基亚砜混合, 以 10%二曱基亚砜 和低分子右旋糖酐浓度降温至 -80'C, 然后转移到、 186°C液氮中深低温保 存。
5、 如权利要求 1-4 中任一项所述的方法制备的植物和蛋白诱导性自体 生殖干细月包。
6、 如权利要求 5所述的植物和蛋白诱导性自体生殖干细胞在制备用于 治疗男女性不孕不育的药物和用于治疗涉及器官再生再造和修复的疾病药 物中的应用;
优选地, 所述疾病为卵巢衰竭;
优选地, 所述自体生殖干细胞用于建立自体生殖千细胞库。
7、 用于使人的体细胞逆向分化的细胞培养液, 其中, 所述培养液选自 细胞培养液 Bl、 B2和 B3, 所述细胞培养液 B1为 RPMI 1640, 并含有淫羊 藿提取物 5-100mg/ml、 鹿茸提取物 5-100mg/ml、 Υ-27632 1-25μΜ、 干细胞 因子 l-100ng ml、 白细胞介素 3 1-lOOng mK 白细胞介素 6 l-100ng/ml; 所 述细胞培养液 B2为 RPMI 1640, 并含有淫羊藿提取物 5-100mg/ml、 鹿茸提 取物 5-100mg/ml、 水蛭提取物 5-100mg/ml、 促红细胞生成素 l-100ng/ml、 干细胞因子 l-100ng/ml、 碱性成纤维细胞生长因子 l-100ng/ml、 Y-27632 1-25μΜ, 白细胞介素 3 l-100ng/ml、 白细胞介素 6 l-100ng/ml、 白细胞介素 11 l-100ng/ml; 所述细胞培养液 B3 为 RPMI 1640, 并含有鹿茸提取物 5-100mg/m 水蛭提取物 5-100mg/ml、 激活素 A l-100ng/ml、 细胞源性 神经营养因子 l-100ng/ml、 促红细胞生成素 l-100ng/ml、 干细胞因子 l-100ng/ml . 碱性成纤维细胞生长因子 l-100ng/ml、 白细胞介素 3 Ι-lOOng/mK 白细胞介素 6 l-100ng/ml、 白细胞介素 1 1 1-lOOng/mK 胰岛素 l-100ng/mU
8、 如权利要求 Ί所述的细胞培养液 B1和 B2在培养人的体细胞使之逆 向分化产生自体生殖干细胞中的应用。
9、如权利要求 7所述的细胞培养液 B3在自体生殖干细胞扩增和传代中 的应用。
10、 一种用于制备自体生殖千细胞的试剂盒, 其中, 所述试剂盒包括如 权利要求 7所述的细胞培养液 B1和 B2;
优选地, 所述试剂盒进一步包括人的体细胞; 所述体细胞包括但不限于 人的脐带血细胞、 胎盘细胞、 皮肤细胞、 血液有核细胞、 脂肪细胞;
优选地, 所述试剂盒进一步包括细胞培养液 B3。
11、 如权利要求 10所述的试剂盒在制备自体生殖干细胞和用于治疗男 女性不孕不育的药物以及用于治疗涉及器官再生再造和修复的疾病药物中 的应用; 优选地, 所述疾病为卵巢衰竭; 建立植物和蛋白诱导性自体生殖干 细胞库的应用。
PCT/CN2011/001393 2010-09-19 2011-08-22 使人的体细胞逆向分化产生自体生殖干细胞的方法、试剂盒及其应用 WO2012034352A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010102889591A CN102399739A (zh) 2010-09-19 2010-09-19 使人的体细胞逆向分化产生自体生殖干细胞的方法、试剂盒及其应用
CN201010288959.1 2010-09-19

Publications (1)

Publication Number Publication Date
WO2012034352A1 true WO2012034352A1 (zh) 2012-03-22

Family

ID=45830953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001393 WO2012034352A1 (zh) 2010-09-19 2011-08-22 使人的体细胞逆向分化产生自体生殖干细胞的方法、试剂盒及其应用

Country Status (2)

Country Link
CN (1) CN102399739A (zh)
WO (1) WO2012034352A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104419658A (zh) * 2013-08-19 2015-03-18 林雄斌 制备雄性非睾丸源性蛋白诱导性自体生殖干细胞的方法、试剂盒、干细胞及应用
CN107287154B (zh) * 2017-05-02 2020-06-30 深圳百年干细胞技术研究院有限公司 一种男性血源性自体精原干细胞的制备方法和试剂盒及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101481679A (zh) * 2009-01-22 2009-07-15 成都军区昆明总医院 鱼卵细胞提取物及其在诱导人成体细胞分化为多能干细胞中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101481679A (zh) * 2009-01-22 2009-07-15 成都军区昆明总医院 鱼卵细胞提取物及其在诱导人成体细胞分化为多能干细胞中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEN YONG-ZHEN ET AL.: "Dissociation and culture in vitro of human embryonic germ line stem cells", CHINESE JOURNAL OF ANATOMY, vol. 28, no. 3, 30 June 2005 (2005-06-30), pages 295 - 298 *
JIANG BIN ET AL.: "Differentiation of embryonic stem cell into chondrocyte cell", ORTHOPEDIC JOURNAL OF CHINA, vol. 17, no. 10, 31 May 2009 (2009-05-31), pages 759 - 761 *
LI FANG: "Bio-assay of human embryonic germ cells", CHINESE MASTER'S THESES FULL-TEXT DATABASE, no. 4, 15 April 2006 (2006-04-15) *
ZHU XIANG QING ET AL.: "Regulating Factors of Somatic cell revers ion differentiation", CHINA HEALTH INNOVATION, vol. 3, no. 15, 31 August 2008 (2008-08-31), pages 24 - 28 *

Also Published As

Publication number Publication date
CN102399739A (zh) 2012-04-04

Similar Documents

Publication Publication Date Title
LU500561B1 (en) In vitro construction method and use of liver organoids
US20240141298A1 (en) Method of isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord, a mesenchymal stem cell population isolated from the amniotic membrane of the umbilical cord and a cell culture medium for isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord
CN102344906B (zh) 一种毛囊干细胞的分离培养方法
MX2008005751A (es) Metodo de aislamiento y uso de celulas derivadas del tejido del cordon umbilical del primer trimestre.
EP2248887A1 (en) A method for constructing human placental mesenchymal cells library which is suitable for clinical application
Gritti et al. Cultures of stem cells of the central nervous system
Benda et al. Urine as a source of stem cells
BR112020020092A2 (pt) método de induzir ou melhorar propriedades de cicatrização de feridas de células tronco mesenquimais
CN109735499B (zh) 新生牛睾丸支持细胞永生化细胞系及其建立方法和应用
Young et al. Cryopreservation of embryonic chick myogenic lineage-committed stem cells
CN113881624A (zh) 一种细胞诱导的方法
WO2012034352A1 (zh) 使人的体细胞逆向分化产生自体生殖干细胞的方法、试剂盒及其应用
RU2648162C2 (ru) Способ получения ростовой добавки на основе лизата тромбоцитов из тромбоцитарной массы доноров к среде для наращивания клеточной массы стволовых, прогениторных, дифференцированных и опухолевых клеток
CN109207422B (zh) 一种欧洲鳗鲡肾脏细胞系ek及其应用
CN105087466B (zh) 诱导脐带间充质干细胞向角膜上皮细胞分化的培养基和方法
WO2012034348A1 (zh) 逆向分化体细胞产生造血干细胞的培养液、方法及用途
CN105683358B (zh) 将从间充质干细胞诱导的多能干细胞分化为脂肪细胞的方法
CN113215083B (zh) 一种大菱鲆肝实质细胞系的建立方法及细胞系
CN107787960B (zh) 视网膜色素上皮细胞的冻存液及其应用
CN106701666A (zh) 一种诱导人羊膜间充质干细胞向心肌样细胞分化的诱导液及方法
CN107058225A (zh) 一种复合诱导培养基以及采用该培养基诱导脐带间充质干细胞成神经元样细胞的方法
KR101010077B1 (ko) 미분화 인간배아줄기세포 유래 배양 조성물을 이용한 소 난자의 체외 배양 방법
CN111484971A (zh) 血源性女性自体生殖干细胞的制备方法和试剂盒及应用
CN108603168B (zh) 从卵泡抽提物中获得雌性生殖干细胞的方法
CN105039239A (zh) 细胞转化诱导液及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11824423

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11824423

Country of ref document: EP

Kind code of ref document: A1